Veraxa Biotech appointed Raju Willener as CFO effective immediately on September 4, 2026, naming him principal financial and accounting officer after experience overseeing portfolios exceeding CHF 30 billion. The appointment matters because he is tasked with strengthening Capital strategy, disciplined capital allocation and strategic opportunities as the oncology pipeline advances.
Key Highlights
- Veraxa Biotech appointed Raju Willener as chief financial officer effective immediately on September 4, 2026.
- Willener will serve as the company’s principal financial officer and principal accounting officer.
- Before joining Veraxa, he served as Exentis Group AG’s director of corporate development and became its chief financial officer in 2025.
Veraxa Biotech AG - Post de-SPAC (NASDAQ: VRXA) appointed Raju Willener as chief financial officer effective immediately on September 4, 2026. He will serve as the company’s principal financial officer and principal accounting officer, reporting to Chief Executive Officer and Co-Founder Christoph Antz, Ph.D. Willener brings international capital-markets and corporate-finance experience to Veraxa.
Willener Takes Principal Finance Role
Willener previously worked at Exentis Group AG as director of corporate development before becoming its chief financial officer in 2025. His responsibilities there included mergers and acquisitions, financial strategy and key corporate functions. Carl von Halem is identified as Veraxa’s former CFO.
Capital Strategy Tied to Oncology Pipeline
Veraxa said Willener will support its BiTAC platform and oncology pipeline by helping strengthen capital strategy, assess strategic opportunities and maintain disciplined execution. The announcement also says he will support disciplined capital allocation and pursue opportunities that can accelerate development of the pipeline. Willener said he would work with Antz and the Leadership team on financial and capital-markets strategy. The company also linked the role to long-term value creation for shareholders.
FAQs
Q: Who is Veraxa Biotech’s new CFO?
A: Raju Willener is Veraxa Biotech’s new chief financial officer. He also serves as the company’s principal financial officer and principal accounting officer, reporting to Christoph Antz, Ph.D.
Q: What experience does Raju Willener bring to Veraxa Biotech?
A: Before joining Veraxa, he served as Director of Corporate Development at Exentis Group AG and became its Chief Financial Officer in 2025. He led M&A initiatives, financial strategy and key corporate functions.
Q: How will the CFO appointment affect Veraxa Biotech?
A: Veraxa said Willener will support capital strategy, disciplined capital allocation and strategic opportunities. The announcement says his expertise will support the company’s BiTAC platform and oncology pipeline.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.